Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Other Non Operating Income (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Other Non Operating Income for 6 consecutive years, with $31000.0 as the latest value for Q1 2020.

  • On a quarterly basis, Other Non Operating Income rose 444.44% to $31000.0 in Q1 2020 year-over-year; TTM through Dec 2020 was $31000.0, a 72.22% increase, with the full-year FY2020 number at $31000.0, up 72.22% from a year prior.
  • Other Non Operating Income was $31000.0 for Q1 2020 at Marker Therapeutics, down from $98000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $6.1 million in Q4 2016 to a low of -$3.0 million in Q1 2016.
  • A 5-year average of $252042.7 and a median of $4000.0 in 2017 define the central range for Other Non Operating Income.
  • Biggest YoY gain for Other Non Operating Income was 900.0% in 2018; the steepest drop was 1953.33% in 2018.
  • Marker Therapeutics' Other Non Operating Income stood at $6.1 million in 2016, then tumbled by 99.93% to $4000.0 in 2017, then skyrocketed by 1350.0% to $58000.0 in 2018, then surged by 68.97% to $98000.0 in 2019, then crashed by 68.37% to $31000.0 in 2020.
  • Per Business Quant, the three most recent readings for MRKR's Other Non Operating Income are $31000.0 (Q1 2020), $98000.0 (Q4 2019), and -$64000.0 (Q3 2019).